Your search for lurasidone returned 77 results

Researchers prospectively and systematically followed patients with mood disorder receiving lurasidone to assess incidences of tardive syndromes.

Researchers investigated whether lurasidone monotherapy would improve health-related quality of life.

Researchers examined hospitalization rates among pediatric patients with bipolar disorder who received treatment with atypical antipsychotic drugs.

Researchers assessed data from short-term studies with open-label extensions among adults and adolescents with bipolar depression to assess the impact of lurasidone on treatment-emergent mania.

Investigators analyzed the potential metabolic effects of lurasidone in a sample of patients with bipolar I depression.

Compared with olanzapine and aripiprazole, lurasidone was linked with lower risk for all-cause and psychiatric hospitalization in pediatric patients.

These data suggest that lurasidone is effective in treating major depressive disorder with manic features without introducing sexual dysfunction.

Researchers compared hospital admission rates in patients with schizophrenia who switched to antipsychotic monotherapy with lurasidone or quetiapine.

Adjunctive lurasidone improved syndromal depression and maintained euthymia in patients with bipolar disorder.

In pediatric patients with bipolar I depression, long-term treatment with lurasidone 20 mg/day is effective in reducing depressive symptoms.

Safety and efficacy of lurasidone monotherapy were assessed in children and adolescents with bipolar I depression.

Lurasidone reduced agitation in patients with acute exacerbation of schizophrenia.

Researchers evaluated the safety and efficacy of lurasidone in children and adolescents with bipolar depression.

Lurasidone was linked with improvements in depression and anxiety in patients with major depressive disorder with mixed features and co-occurring anxiety.

Lurasidone is an atypical antipsychotic that has demonstrated efficacy in the treatment of schizophrenia in adolescents.

Bipolar depression treatment response to lurasidone between baseline and week 2 indicates later treatment success.

Sunovion have announced positive results from a study evaluating Latuda (lurasidone HCI) for the treatment of schizophrenia in adolescents aged 13 to 17 years old.

Analysis conducted by German agency found that lurasidone is not any better than older atypical antipsychotics in treating schizophrenia.

Lurasidone HCl 20mg, 40mg, 60mg, 80mg, 120mg; tabs.

Investigators searched publication databases through June 2021 for studies reporting metabolic effects from antipsychotic treatments in the setting of schizophrenia.

Researchers sought to determine if lumateperone therapy improves quality of life and functional impairment in patients with bipolar disorder.

Reviewed August 2022

Compared with healthy individuals, patients with bipolar disorder display reduced connectivity in regions of the brain associated with cognitive processing. Researchers examined whether acute medication treatment may resolve functional connectivity abnormalities in youth with bipolar disorder.

This current study builds on a 2007 report that found an increasing rate of bipolar disorder diagnosis among youth between 1996 and 2004.

Researchers conducted an update of a 2015 Cochrane Review to obtain more current information about ketamine and other glutamate receptor modulators in bipolar depression.

Researchers conducted a meta-analysis of 26 randomized clinical trials that compared fixed doses of first- and second-generation antipsychotic medications.

A systematic review examined the metabolic and cardiovascular adverse effects in commonly prescribed second-generation antipsychotics.

Researchers sought to investigate the feasibility of regular systematic case reviews through telepsychiatric consultation to improve workforce training and development within rural primary care clinics.

In patients with unipolar depression, treatment with low-dose and high-dose tDCS resulted in improvements in verbal learning and working memory, selective attention, and information processing speed.

In long-term care facilities, the rate of antipsychotic use in patients with PD ranges from 15% to 30%; however, the efficacy of AAPs in these patients has not been evaluated in large clinical trials.